In a move that Novartis (IW 1000/71) hopes will propel the company to market leader position on generic dermatology medicines, the company announed on May 3 that it will buy dermatology generics group Fougera for $1.525 billion.
Novartis said it would pay cash for the acquisition and that Fougera will be integrated into its generic pharmaceutical division.
"The combined businesses will become the number one global company in generic dermatology medicines, with estimated annual global sales of nearly $620 million, primarily in the U.S.," said the Basel-based group.
Fougera posted sales reaching $429 million in 2011 and employs about 700 people.
Copyright Agence France-Presse, 2012
See Also
Novartis Cuts 2,000 U.S. Jobs After Patent Loss
